Ozempic and Mounjaro are licensed for type 2 diabetes. Wegovy is licensed for chronic weight management in adults with obesity or overweight with comorbidities. Any weight loss from Ozempic or Mounjaro outside diabetes treatment is off-label.
But how do you pick the best one?
This article compares them, including side effects, safety, price, how well they work for weight loss, if you can get them in the UK, and other options if they don’t work for you.
Before comparing them in detail, it’s important to understand what type of medicines they are. Ozempic and Wegovy are GLP-1 receptor agonists. It means they mimic the gut hormone GLP-1 to help regulate appetite, improve blood sugar, and slow digestion.
Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist. It targets two metabolic pathways. This leads to potentially stronger effects on blood glucose control and weight loss.
Quick Answer: Ozempic and Mounjaro are injectable treatments licensed in the UK for type 2 diabetes. Wegovy is licensed for chronic weight management. Weight-loss use of Ozempic and Mounjaro outside diabetes treatment is off-label and requires clinical supervision.
- Wegovy is approved for weight management and obesity.
- Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors. It is used in type 2 diabetes and is also known for producing stronger weight-loss effects.
- Mounjaro usually causes the most weight loss. Wegovy is moderate with fewer side effects, and Ozempic mainly controls blood sugar.
What Are Ozempic, Wegovy, and Mounjaro?
Ozempic, Wegovy, and Mounjaro all belong to a group of injectable medicines. They are used to support blood sugar control and weight management. But each one has its own purpose, dosage, and clinical role. Let’s look at them in detail.
Ozempic
Ozempic (semaglutide) is a GLP-1 receptor agonist used primarily to treat type 2 diabetes. It helps:
- Regulate appetite
- Slow digestion
- Increase insulin release when blood sugar rises
- Improve long-term blood glucose control
Although Ozempic is not officially licensed for weight loss in the UK. But many people experience weight reduction as a secondary effect. This has contributed to its rising popularity.
Administration: Ozempic is taken as a weekly injection, with doses typically starting at 0.25 mg and gradually increasing.
Wegovy
Wegovy (also semaglutide) is closely related to Ozempic but is offered in a higher strength. It is approved specifically for weight loss in adults with obesity or weight-related medical conditions.
It works in the same way as Ozempic by activating GLP-1 receptors. However, the higher dosing allows for stronger appetite suppression. This results in greater weight-loss outcomes.
Administration: Also a once-weekly injection, with doses titrated up to 2.4 mg.
Mounjaro
Mounjaro (tirzepatide) is different. It is a dual GLP-1 and GIP receptor agonist, meaning it acts on two hormones instead of one.
This dual action may offer additional benefits for:
- Reducing appetite
- Improving blood sugar control
- Enhancing metabolic efficiency
Mounjaro is licensed for type 2 diabetes. Many people are prescribed it privately for weight management due to promising clinical results.
Administration: Mounjaro is also taken as a weekly injection. It’s a structured dose escalation ranging from 2.5 mg to 15 mg. But it primarily depends on individual treatment plans.
Mounjaro vs Ozempic
The difference between Ozempic and Mounjaro comes from how they act on the body. Ozempic is a GLP-1 receptor agonist, while Mounjaro is a dual GLP-1/GIP agonist. It offers broader metabolic effects.
If you’re wondering: Is Mounjaro the same as Ozempic?
The answer is no. Both medications are injectable treatments that help manage blood sugar. But they work through different hormonal pathways.
Ozempic is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1 to regulate appetite, slow digestion, and improve insulin response. Meanwhile Mounjaro (tirzepatide), is a dual GLP-1/GIP receptor agonist. It targets both GLP-1 and GIP hormones. This dual action affects two metabolic pathways, which can lead to broader improvements in blood sugar control and additional benefits in weight management.
While both drugs share some similar effects, Mounjaro’s dual mechanism makes it distinct from Ozempic in how it works inside the body.
Mounjaro vs Wegovy
The key difference between Wegovy and Mounjaro is in their mechanisms. Wegovy is high-dose semaglutide. It’s a GLP-1 agonist approved specifically for weight loss.
Meanwhile, Mounjaro uses dual activity for potentially stronger appetite and glucose control. Mounjaro is licensed for type 2 diabetes, and Wegovy is licensed for obesity/weight management. Both are administered via weekly subcutaneous injections, but their licensed indications differ.
Ozempic vs Wegovy
Ozempic and Wegovy contain the same ingredient, semaglutide. But they have different strengths and for different purposes.
Ozempic is licensed for type 2 diabetes. Whereas Wegovy is the higher-dose version authorised for weight loss.
They might look similar, but they are prescribed differently. That’s why at Coxheath Pharmacy, we make distinct dosing schedules and treatment goals. It helps you achieve your weight goals.
Ozempic vs Wegovy vs Mounjaro: Comparison Table
| Feature | Ozempic | Wegovy | Mounjaro (Tirzepatide) |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| UK licensed use | Type 2 diabetes (weight loss off-label) | Chronic weight management (obesity/overweight) | Type 2 diabetes; also, MHRA authorisation granted for weight management (2023) |
| Target population | Adults with type 2 diabetes (& obesity via private clinics & consultation) | Adults with obesity or overweight with comorbidities | Adults with type 2 diabetes or overweight/obesity are eligible for weight management |
| Mechanism | Reduces appetite, slows gastric emptying, and improves blood glucose | Same as Ozempic but at a higher dose for obesity | Activates GLP-1 and GIP receptors for stronger metabolic and appetite control |
| Dosing/administration | Weekly subcutaneous injection; titrated | Weekly subcutaneous injection; titrated to target weight-management dose | Weekly subcutaneous injection; titrated according to clinical plan |
| Preference | Often considered when weight loss is secondary | Focused on obesity treatment, may reduce CV risk in eligible adults | Strongest weight-loss potential in UK clinical practice; dual mechanism differentiates it |
Weight Loss Effectiveness
Recent clinical trials suggest that all three medicines can produce meaningful weight loss.
But Mounjaro (tirzepatide) consistently shows the strongest results.
A recent phase‑3 trial comparing tirzepatide vs semaglutide in people living with obesity (without diabetes) reported average weight loss of 20.2% with tirzepatide vs 13.7% with semaglutide over 72 weeks.
Comparison Table: Weight Loss Outcomes
This comparison table will help you get clarity on ozempic vs wegovy vs mounjaro for weight loss.
| Drug | Approx. Average Weight Loss | Study Duration | Typical Population (Diabetic vs Non‑diabetic) |
| Mounjaro (tirzepatide) | ~ 20.2% (at 72 weeks) | 72 weeks (head-to-head obesity trial) | Non‑diabetic adults with obesity/overweight; some data also from people with type 2 diabetes |
| Wegovy (semaglutide high dose) | ~ 13.7% at 72 weeks in head-to-head trial vs tirzepatide | 68–72 weeks in STEP‑like trials / real-world use | Primarily non‑diabetic adults with obesity/overweight |
| Ozempic (semaglutide, diabetes dosing) | ~ 5–10% (in many diabetes trials; weight loss is secondary) | ~ 6–12 months (varied by study) | Adults with type 2 diabetes (weight loss not primary indication) |
These are typical mean (average) results. But individual results may vary widely depending on diet, lifestyle, adherence, and starting weight.
Do Results Differ Between Diabetic And Non‑diabetic Patients?
Yes, and you need to understand the reason behind this:
- In non‑diabetic obesity trials, weight loss tends to be larger (especially with tirzepatide or high-dose semaglutide). It’s most likely because metabolism, insulin resistance, and background treatments differ.
- In people with type 2 diabetes, weight loss may be less dramatic. Although tirzepatide still outperforms semaglutide on average.
- Achieving high weight-loss percentages (>15–20%) is more common in non‑diabetic studies. Particularly where obesity rather than diabetes is the main target.
Which Drug Is Generally Most Potent for Weight Loss?
Maybe you should opt for Wegovy or Mounjaro for weight loss? Or Ozempic, because it’s getting so much hype?
There are several options in the market, but you need to identify your goal. Is your main goal maximum weight reduction?
Then Mounjaro (tirzepatide) is the most potent among the three. It’s primarily beneficial for non‑diabetic overweight or obese adults.
Narrow the list as per your goals. You can connect with our expert pharmacists for detailed guidance as well.
Side Effects
These medications often cause nausea, vomiting, diarrhoea, or constipation. It can even lead to reduced appetite, mild headaches, fatigue, and minor injection-site reactions such as redness or swelling.
When people hear about these side effects, a common concern naturally comes up: is Wegovy safer than Mounjaro?
It’s important to understand that most side effects are usually mild to moderate. They tend to improve as your body adjusts to the medication.
However, there are some rare but more serious complications to be aware of as well:
- Pancreatitis: Severe abdominal pain, nausea, vomiting. Must stop medication and seek urgent care.
- Gallbladder problems: Gallstones or cholecystitis, especially with rapid weight loss.
- Severe GI reactions: Persistent vomiting or diarrhoea can cause dehydration.
- Hypoglycaemia: Mainly if combined with insulin or sulphonylurea.
- Other rare issues: Metabolic effects; monitor under clinical supervision.
Side Effects Comparison
All three drugs Ozempic, Wegovy and Mounjaro share overlapping side effect profiles. It is largely because they act on similar biological pathways (appetite regulation, digestion).
| Ozempic vs Wegovy vs Mounjaro Side Effects | ||
| Drug | Common Side Effects (Frequency) | Serious/Rare Considerations |
| Ozempic (semaglutide, diabetes dose) | Mild–moderate GI issues (nausea, diarrhoea/constipation), reduced appetite, injection‑site reaction | Lower dose reduces risk, but still potential GI impact; long-term safety in high doses for obesity is not established |
| Wegovy (semaglutide high dose) | Similar GI side effects: nausea, vomiting, indigestion, appetite suppression; more pronounced at higher doses used for weight loss | Higher dose correlates with increased GI burden; long-term adherence may be challenged by tolerability issues |
| Mounjaro (tirzepatide) | GI symptoms: nausea, vomiting, diarrhoea or constipation; risk is higher with stronger doses/dual mechanism | Greatest efficacy but potentially higher incidence of GI events; rare but requires monitoring (pancreas, gallbladder, metabolic effects) |
Cost & Availability (What You Should Know)
All three drugs are available in the UK, mostly via private prescription or private clinics. However, Public (NHS) access is limited. It’s generally reserved for patients meeting strict criteria (e.g. severe obesity, comorbidities, or type 2 diabetes).
Recent changes (2025) have pushed up the cost of Mounjaro significantly. Because of cost and supply fluctuations, many UK patients now compare Wegovy vs Mounjaro vs Ozempic cost.
Comparative Pricing Guide
Here’s how the costs compare. This can help you evaluate the prices of Ozempic, Wegovy, and Mounjaro.
| Medication | Typical Monthly Cost (UK, private)¹ | Notes on Use/Availability |
| Mounjaro (tirzepatide) | ~ £235–£500 (depending on dose) | Most expensive; dual‑hormone drug; strong weight‑loss potential; limited NHS access |
| Wegovy (semaglutide high dose) | ~ £170–£300 depending on dosage | Licensed for weight management; a common “cheaper alternative to Mounjaro” in the UK market |
| Ozempic (semaglutide, diabetes dosing) | ~ £150–£200 (for typical diabetes treatment) | Least expensive; primary use is diabetes control; weight-loss use is off-label |
What Is A Cheaper Alternative To Ozempic/Mounjaro/Wegovy?
Since Mounjaro has become expensive, many people seek more affordable options. So, is cost or access a huge concern?
Then here are some cheaper alternatives people explore:
- Orlistat (brands: Xenical, Alli): Works by reducing fat absorption in the gut. Oral medication, no injections required.
- Liraglutide (e.g., Saxenda): Appetite-regulating injection. It’s generally less powerful than tirzepatide or high-dose semaglutide. Can be used when injections like Mounjaro are cost-prohibitive.
- Lifestyle-Based Approaches: Structured diet, exercise, and behavioural programmes. Most affordable, widely accessible, and sustainable long-term.
Safety and Special Considerations
Is Wegovy safer than Mounjaro? Or maybe you should opt for Ozempic?
These are confusions that patients usually have. But you need to understand that every medication is different. So is Mounjaro the same as Ozempic?
Not at all.
But they have a few common side effects and special considerations that you should know.
Who Should Avoid These Medications
- Pregnancy and breastfeeding: Not recommended due to limited safety data. Nursing mothers should consult a healthcare professional before use.
- History of pancreatitis or gallbladder disease: Use is discouraged because these medications can increase risk.
- Thyroid cancer or family history of medullary thyroid carcinoma: Avoid due to regulatory warnings associated with GLP-1 and GLP-1/GIP receptor agonists.
- Renal impairment or severe gastrointestinal disease: Requires specialist supervision and careful monitoring.
- Diabetic gastroparesis: Medications may worsen symptoms; caution is advised.
Safety Profile
There are also several differences in the safety profile of each medication.
Mounjaro (tirzepatide)
Offers the strongest weight-loss effect but may lead to more nausea, vomiting, and diarrhoea. Its dual GLP-1/GIP mechanism can increase metabolic strain. That’s why careful monitoring is essential.
Wegovy
It offers moderate weight-loss potency with generally fewer severe side effects. May provide cardiovascular benefits for some patients. Often considered slightly safer than Mounjaro in terms of gastrointestinal tolerability.
Ozempic
Primarily for glycaemic control, and its weight-loss effects are secondary. Generally mild gastrointestinal side effects and a lower risk of severe complications.
Drug Interactions and Other Considerations
- Hypoglycaemia: Risk increases if combined with insulin or sulphonylureas.
- Other medications: Limited data for combination with some cardiovascular, renal, or liver drugs. So always check with a UK prescriber or pharmacist.
- Rapid weight loss: Can stress the gallbladder, kidneys, or liver. Gradual dosing, proper hydration, and nutrition are important.
Alternatives and Substitutes
Is cost, access, or side effects making Mounjaro or Ozempic challenging? There are several alternatives to consider:
Other GLP-1 or Dual Agonists
Rybelsus (semaglutide)
It is an oral GLP-1 medication primarily for type 2 diabetes. It is taken daily and can sometimes be used off-label for weight management. Thus making it suitable for those who prefer not to inject.
Liraglutide (Saxenda)
Approved for obesity management; daily injections. This Wegovy alternative is less potent than Mounjaro but effective for moderate weight loss.
Zepbound (tirzepatide)
It contains the same active ingredient as Mounjaro. It is a weekly injection that works on both GLP-1 and GIP pathways to aid appetite suppression and blood sugar control.
Non-Pharmaceutical Options
Lifestyle interventions
Structured diet plans, regular physical activity, and behavioural therapy. These remain the safest and most sustainable weight-management strategies.
Structured weight-management programmes
UK programmes such as NHS Weight Management Services or private clinics provide guidance that can complement or sometimes replace medication.
Most of these alternatives are available in the UK through private clinics. NHS prescriptions are limited to eligible patients with specific BMI thresholds or comorbidities.
Globally, availability varies. Some medications may be more accessible in certain EU countries or online pharmacies. But UK patients are advised to use licensed UK sources to ensure safety.
UK-Specific Considerations
Comparing Ozempic vs Wegovy vs Mounjaro UK gives you clarity on which medication is best for you. But it’s important to consider how access differs between NHS and private options.
- Prescription-only: Mounjaro, Ozempic, and Wegovy are prescription-only medications in the UK.
- NHS vs Private Access:
- NHS access is limited, mostly for type 2 diabetes or severe obesity with comorbidities.
- Private clinics can provide access for weight management, but cost is a consideration.
Weight loss is an important journey. It’s important to budget it properly so you don’t face any issues during treatment. Here’s a range of these medications in the UK.
- Mounjaro: £235–£500 per month (private)
- Wegovy: £170–£300 per month
- Ozempic: £150–£200 per month (for diabetes dosing)
Private clinics are often the main route for non-diabetic weight management. These prescriptions are issued after consultation and monitoring. However, the NHS is highly restricted. The eligibility depends on BMI, comorbidities, and clinician assessment.
Frequently Asked Questions
What drug are celebrities taking to lose weight?
In the UK, medications like Mounjaro and Ozempic have attracted attention for their effectiveness in supporting weight loss. Celebrities often use Ozempic. But professional medical guidance is essential before considering these treatments.
Does Ozempic reduce tummy fat?
Ozempic may cause secondary weight reduction in adults with type 2 diabetes, but it is not licensed for obesity treatment under PGD. But combining the medication with a healthy diet and regular exercise enhances fat reduction.
Can I switch from Wegovy to Mounjaro?
Switching is possible under UK medical supervision. A clinician will evaluate your current dose, health conditions, and weight-loss goals before recommending a transition to ensure safety and effectiveness.
Is semaglutide or tirzepatide better for weight loss?
Mounjaro (tirzepatide) generally produces more significant weight loss than semaglutide-based medications like Ozempic or Wegovy, though individual responses vary. Safety, cost, and tolerability also influence which drug is better for a specific patient.
Which weight loss injection has the least side effects?
Wegovy tends to have slightly fewer gastrointestinal side effects than Mounjaro. Ozempic is generally well tolerated by diabetes patients, with moderate weight-loss benefits.
Can you take Mounjaro while breastfeeding?
Mounjaro is not recommended during breastfeeding due to limited safety data. UK nursing mothers should discuss safe alternatives with a healthcare professional.
What are the cheaper alternatives to Mounjaro or Ozempic in the UK?
Wegovy is often considered a more affordable alternative, while lifestyle interventions, Orlistat, and liraglutide-based regimens provide safe and cost-effective substitutes for weight management.
Conclusion
Choosing between Ozempic, Wegovy, and Mounjaro in the UK depends on different factors. Mounjaro generally offers the strongest weight-loss results. Wegovy provides a significant reduction with slightly fewer gastrointestinal effects. Meanwhile, Ozempic is primarily for diabetes management with moderate weight loss.
Costs vary, with Mounjaro usually the most expensive and Ozempic often the most affordable. Individual factors such as weight-loss goals, existing medical conditions, budget, and local availability determine the best option.
Consulting a UK healthcare professional ensures a personalised, safe, and effective treatment plan. So if you’ve any queries regarding weight loss, then get in touch with Coxheath Pharmacy now.
